leisure time -WSS

leisure time

author：Wikipedia 2025-09-06 01:57:51 - browse：3

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： STAT Summit: The economic case for universal basic health care

hotspot

WSS

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Brazil's Jair Bolsonaro is barred from running for office until 2030

Questions loom on AstraZeneca cancer drug as safety concerns ebb

UnitedHealth wins $3.3 billion takeover of Amedisys

The simple reason for the increase in autism diagnosis

STAT Readout Newsletter: Biotech news today

Wikipedia

leisure time

hotspot

What does generative AI mean for health care? We asked experts

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Hollywood unions extend contract negotiations for actors

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Continuity nursing helped my family in our darkest PICU moments

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Bright Health sells Medicare Advantage business to Molina

Results on Novartis prostate cancer therapy could expand its use

How one medical school became remarkably diverse

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

leisure time

STAT Summit: Meghan O’Rourke on making chronic illness visible

STAT Readout: Friday, Oct. 20 biotech updates

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Why do we get seasonal allergies?

Smaller biotechs seek to piggyback on weight loss drug boom

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

hotspot

hotspot

hotspot

Wikipedia